Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Alternate Symbol(s):  CRPOF

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by hoffbagon Aug 25, 2021 1:25pm
78 Views
Post# 33761615

RE:RE:RE:RE:RE:Quarterly Report

RE:RE:RE:RE:RE:Quarterly ReportI understand lumpiness, seasonality, product life cycle OR getting more specific, customer/supply chain issues, fx, pricing pressure, product mix..... That is how mgmt needs to explain.

In this instance I would be surprised to see a revenue shortfall unless channels were stuffed to the wazoo last quarter.  I also wouldnt expect margin difficulties (cost up / price up) or any significant changes due to FX (in fact pick up for future q's due to weakening CDN$ as of late).  There is potential tailwind from the recall.  Right now most companies have received a GOLDEN ticket for price increases or surcharges (blame it on Covid....).  

Revenue is the lifeblood of a business (bird in the hand).  Product development is MAYBE future revenue (two birds in the bush)......


 

<< Previous
Bullboard Posts
Next >>